Cti Biopharma Corp
CTICDelisted Jun 26, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000891293
Cti Biopharma Corp was delisted on Jun 26, 2023; its insiders filed their last Form 4 on Jun 28, 2023; 133 institutions reported holding it in 13F filings for Q1 2023, worth $475.2M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cti Biopharma Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cti Biopharma Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Biotechnology Value Fund L P | Director, 10% Owner, Other: See Explanation of Responses | 0Indirect | Jun 28, 2023 | 0 |
| BVF Partners L P | Director, 10% Owner, Other: See Remarks | 0Indirect | Jun 28, 2023 | 0 |
| BVF Inc | Director, 10% Owner, Other: See Explanation of Responses | 0Indirect | Jun 28, 2023 | 0 |
| Biotechnology Value Fund II LP | Director, Other: See Explanation of Responses | 0Indirect | Jun 28, 2023 | 0 |
| Lampert Mark N | Director, 10% Owner, Other: See Explanation of Responses | 0Indirect | Jun 28, 2023 | 0 |
| Biotechnology Value Trading Fund OS LP | Director, Other: See Explanation of Responses | 0Indirect | Jun 28, 2023 | 0 |
| BVF Partners OS Ltd. | Director, Other: See Explanation of Responses | 0Indirect | Jun 28, 2023 | 0 |
| BVF I GP LLC | Director, 10% Owner, Other: See Explanation of Responses | 0Indirect | Jun 28, 2023 | 0 |
| BVF II GP LLC | Director, Other: See Explanation of Responses | 0Indirect | Jun 28, 2023 | 0 |
| BVF GP Holdings LLC | Director, 10% Owner, Other: See Explanation of Responses | 0Indirect | Jun 28, 2023 | 0 |
| Kirske David | EVP, Chief Financial Officer | 0 | Jun 26, 2023 | 0 |
| Craig Adam R | President and CEO | 0 | Jun 26, 2023 | 0 |
| Fischer Laurent | Director | – | Jun 26, 2023 | 0 |
| Parkinson David Ross | Director | – | Jun 26, 2023 | 0 |
| Perry Matthew D | Director | 0 | Jun 26, 2023 | 0 |
| Metzger Michael A | Director | 0 | Jun 26, 2023 | 0 |
| Tuckson Reed Vaughn | Director | 0 | Jun 26, 2023 | 0 |
| Parks Diane L. | Director | – | Jun 26, 2023 | 0 |
| Fong James K | EVP & Chief Commercial Officer | 0 | Jun 26, 2023 | 0 |
| Seeley Bruce J. | EVP, Chief Operating Officer | 43,905 | Mar 11, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 2, 2021 (view filing) | Dec 2 | Same day | Craig Adam RPresident and CEO | PPurchase | +3.50K | $1.53 | +$5.34K | +35.0%13.5K after | 2 lots |
| Jun 3, 2022 (view filing) | Jun 1-3 | 2 days | Craig Adam RPresident and CEO | SSale | −72.2K | $6.00 | −$433.5K | −81.2%16.7K after | From original3 lots |
| Jun 16, 2022 (view filing) | Jun 14 | 2 days | Kirske DavidEVP, Chief Financial Officer | SSale | −10.0K | $5.50 | −$55.0K | −57.5%7.40K after | |
| Jun 17, 2022 (view filing) | Jun 17 | Same day | Kirske DavidEVP, Chief Financial Officer | SSale | −60.0K | $6.21 | −$372.5K | −89.0%7.40K after | 2 lots |
| Jul 6, 2022 (view filing) | Jul 1-6 | 5 days | Craig Adam RPresident and CEO | SSale | −72.2K | $6.03 | −$435.3K | −76.0%22.9K after | 3 lots |
| Jul 7, 2022 (view filing) | Jul 5 | 2 days | Metzger Michael ADirector | SSale | −91.5K | $6.08 | −$556.0K | −82.0%20.1K after | 4 lots |
| Jul 11, 2022 (view filing) | Jul 7 | 4 days | Metzger Michael ADirector | SSale | −20.1K | $6.51 | −$131.0K | −100.0%0 after | 6 lots |
| Aug 11, 2022 (view filing)5:52 PM ET | Aug 9 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner, Other: See Explanation of Responses | SSaleCommon Stock, par value $0.001 | −7.21M | $6.12 | −$44.1M | −99.7%19.8K after | 3 lots |
| Aug 11, 2022 (view filing)5:52 PM ET | Aug 9 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner, Other: See Explanation of Responses | SSaleCommon Stock, par value $0.001 | −1.29M | $6.12 | −$7.89M | −99.5%6.15K after | |
| Aug 16, 2022 (view filing) | Aug 16 | Same day | Craig Adam RPresident and CEO | PPurchase | +5.00K | $5.50 | +$27.5K | +21.9%27.9K after | |
| Sep 14, 2022 (view filing) | Sep 12 | 2 days | Craig Adam RPresident and CEO | SSale | −242.3K | $6.43 | −$1.56M | −89.7%27.9K after | |
| Sep 20, 2022 (view filing) | Sep 16 | 4 days | Kirske DavidEVP, Chief Financial Officer | SSale | −22.6K | $6.02 | −$136.0K | −57.2%16.9K after | |
| Oct 3, 2022 (view filing) | Sep 29-Oct 3 | 4 days | Kirske DavidEVP, Chief Financial Officer | SSale | −141.0K | $6.05 | −$853.3K | −89.3%16.9K after | 4 lots |
| Oct 6, 2022 (view filing) | Oct 4 | 2 days | Kirske DavidEVP, Chief Financial Officer | SSale | −2.11K | $6.26 | −$13.2K | −11.1%16.9K after | 3 lots |
| Nov 10, 2022 (view filing) | Nov 8 | 2 days | Metzger Michael ADirector | SSale | −91.5K | $5.59 | −$511.2K | −100.0%0 after | 3 lots |
| Nov 14, 2022 (view filing) | Nov 9-10 | 5 days | Craig Adam RPresident and CEO | SSale | −242.3K | $6.00 | −$1.45M | −89.7%27.9K after | 10 lots |
| Jan 3, 2023 (view filing) | Dec 29, 2022-Jan 3, 2023 | 5 days | Kirske DavidEVP, Chief Financial Officer | SSale | −54.0K | $6.01 | −$324.5K | −75.9%17.1K after | 5 lots |
| Jan 3, 2023 (view filing) | Dec 29, 2022-Jan 3, 2023 | 5 days | Craig Adam RPresident and CEO | SSale | −115.6K | $6.01 | −$694.4K | −79.7%29.4K after | 5 lots |
| Jan 26, 2023 (view filing) | Jan 24 | 2 days | Fong James KEVP & Chief Commercial Officer | SSale | −100.0K | $6.00 | −$600.0K | −96.6%3.56K after | |
| Jan 26, 2023 (view filing) | Jan 24 | 2 days | Craig Adam RPresident and CEO | SSale | −85.3K | $6.00 | −$511.9K | −74.3%29.4K after | 2 lots |